DHR- Danaher Corporation
Healthcare · Diagnostics & Research
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
Strong BuyWall Street consensus from 23 analysts
12-Month Price Target
$229.09
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $200.14
Graham Number
√(22.5 × EPS × Book Value)
$97.09
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$16.60
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
8/10
80% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
7.6%Return on equity - measures how efficiently capital is used
Positive profit margin
15.9%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+5.5%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+59.7%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
52.97×Low financial leverage reduces risk of distress
Current ratio above 1
1.65×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$924M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
0.80%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 20, 2026
38
days
EPS (TTM)
$5.60
P/E (TTM)
35.7
Fwd P/E
21.5
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
0.80%
5Y Avg Annual
$1.0070
Last Payment
$0.4000
Ex-Date
06/26/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest06/26/2026 | 07/31/2026 | $0.4000 | 0.80% |
03/27/2026 | 05/01/2026 | $0.4000 | 0.80% |
12/26/2025 | 01/30/2026 | $0.3200 | 0.64% |
09/26/2025 | 10/31/2025 | $0.3200 | 0.64% |
06/27/2025 | 08/01/2025 | $0.3200 | 0.64% |
03/28/2025 | 05/02/2025 | $0.3200 | 0.64% |
12/27/2024 | 01/31/2025 | $0.2700 | 0.54% |
09/27/2024 | 11/01/2024 | $0.2700 | 0.54% |
Magic Number
Shares needed to self-fund your next purchase
$200.14
Price
$0.4000
Last div. (quarterly)
501
shares
Own 501 DHR shares ($100,270.14) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$100,270.14
New shares / year
+4 shares
Dividend Calculator
0.80% yieldEstimate DHR dividend income at the current rate.
Per year
$79.94
Per month
$6.66
≈ 50 shares at $1.6/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
DHR vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Sector
Healthcare
Industry
Diagnostics & Research
Location
Washington, United States
Employees
58,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Danaher Corporation (DHR) stock trades at $200.14, down 0.19% on the day. With a market capitalization of $140.70 billion, DHR is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 35.7, a forward P/E of 21.5 and earnings per share (EPS) of $5.60. Over the most recent period the company reported 6% year-over-year revenue growth and a net profit margin of 15.9%. Below you'll find DHR's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
DHR - Frequently Asked Questions
Is Danaher Corporation (DHR) a good stock to buy in 2026?
Danaher Corporation (DHR) shows strengths such as a strong 16% net margin, while risks include high leverage (debt/equity of 53.0). Whether DHR is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is DHR's stock price today?
Danaher Corporation (DHR) trades at $200.14, down 0.19% on the session. Prices on this page update throughout the trading day.
Does DHR pay a dividend?
Yes. Danaher Corporation pays an annual dividend of $1.60 per share, a dividend yield of 0.80%. The most recent ex-dividend date was June 26, 2026. Its payout ratio is about 26% of earnings.
Is DHR overvalued?
With a P/E ratio of 35.7×, DHR is valued above the broad-market average for the healthcare sector. Its PEG ratio is 1.23. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is DHR's market cap?
Danaher Corporation (DHR) has a market capitalization of $140.70 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.